Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of lymph node count in surgically treated patients with T2-4 stage nonmetastatic adrenocortical carcinoma.
Assad A, Barletta F, Incesu RB, Scheipner L, Morra S, Baudo A, Garcia CC, Tian Z, Ahyai S, Longo N, Chun FKH, Shariat SF, Tilki D, Briganti A, Saad F, Karakiewicz PI. Assad A, et al. Among authors: barletta f. Urol Oncol. 2024 Apr 22:S1078-1439(24)00423-X. doi: 10.1016/j.urolonc.2024.04.003. Online ahead of print. Urol Oncol. 2024. PMID: 38653591
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun FKH, De Cobelli O, Saad F, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. Barletta F, et al. Urol Oncol. 2023 Mar;41(3):147.e1-147.e6. doi: 10.1016/j.urolonc.2022.10.027. Epub 2022 Nov 22. Urol Oncol. 2023. PMID: 36428165
Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis.
Panunzio A, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu RB, Law KW, Tian Z, Tafuri A, Tilki D, De Cobelli O, Chun FKH, Terrone C, Briganti A, Saad F, Shariat SF, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Panunzio A, et al. Among authors: barletta f. J Surg Oncol. 2023 Mar;127(4):560-567. doi: 10.1002/jso.27161. Epub 2022 Nov 26. J Surg Oncol. 2023. PMID: 36434748
Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Panunzio A, et al. Among authors: barletta f. Urol Oncol. 2023 Feb;41(2):110.e7-110.e14. doi: 10.1016/j.urolonc.2022.11.009. Epub 2022 Nov 28. Urol Oncol. 2023. PMID: 36456452
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer.
Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, Briganti A, de Cobelli O, Chun FKH, Graefen M, Mirone V, Ahyai S, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Tappero S, et al. Among authors: barletta f. Urol Oncol. 2023 Jul;41(7):326.e9-326.e16. doi: 10.1016/j.urolonc.2023.01.015. Epub 2023 Mar 5. Urol Oncol. 2023. PMID: 36882338
Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML, Barletta F, Tappero S, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Ahyai S, Longo N, Tilki D, Chun FKH, Terrone C, Briganti A, de Cobelli O, Musi G, Karakiewicz PI. Piccinelli ML, et al. Among authors: barletta f. Eur Urol Focus. 2023 Sep;9(5):799-806. doi: 10.1016/j.euf.2023.03.014. Epub 2023 Apr 4. Eur Urol Focus. 2023. PMID: 37024421
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma.
Piccinelli ML, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Ahyai S, Longo N, Tilki D, Briganti A, Chun FKH, Terrone C, de Cobelli O, Musi G, Karakiewicz PI. Piccinelli ML, et al. Among authors: barletta f. Eur Urol Open Sci. 2023 Jun 13;53:109-115. doi: 10.1016/j.euros.2023.05.005. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37441347 Free PMC article.
Conditional survival of stage III non-seminoma testis cancer patients.
Incesu RB, Barletta F, Tappero S, Morra S, Garcia CC, Scheipner L, Piccinelli ML, Tian Z, Saad F, Shariat SF, de Cobelli O, Ahyai S, Chun FKH, Longo N, Terrone C, Briganti A, Tilki D, Graefen M, Karakiewicz PI. Incesu RB, et al. Among authors: barletta f. Urol Oncol. 2023 Oct;41(10):435.e11-435.e18. doi: 10.1016/j.urolonc.2023.06.005. Epub 2023 Aug 7. Urol Oncol. 2023. PMID: 37558516
Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites.
Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, Briganti A, de Cobelli O, Chun FKH, Graefen M, Longo N, Ahyai S, Carmignani L, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Tappero S, et al. Among authors: barletta f. Urol Oncol. 2024 Jan;42(1):22.e23-22.e31. doi: 10.1016/j.urolonc.2023.08.014. Epub 2023 Sep 28. Urol Oncol. 2024. PMID: 37775340
212 results